Q4 2025 Neumora Therapeutics Inc Earnings Call Transcript
Key Points
- Neumora Therapeutics Inc (NMRA) reported positive results from the Phase Ib study of NMRA-511, showing a clinically meaningful effect size in Alzheimer's disease agitation with a favorable safety profile.
- The company has fully enrolled the KOASTAL-2 and KOASTAL-3 studies for navacaprant, with data expected in the second quarter of 2026.
- Neumora announced promising data for NMRA-898, their lead program in the M4 PAM franchise, showing potential for development in schizophrenia.
- The company reported class-leading weight loss data for NMRA-215 in a 12-week diet-induced obesity study, supporting its potential in obesity treatment.
- Neumora has a strong financial position with $182.5 million in cash, expected to support operations into the third quarter of 2027.
- Unexpected adverse findings were observed in a 13-week rat toxicology study for NMRA-215, leading to a delay in clinical trials until the first quarter of 2027.
- The company has paused development of NMRA-861, another M4 PAM, although it remains a potential candidate for future development.
- There are risks and uncertainties associated with forward-looking statements, which could result in actual results differing materially.
- The company faces challenges in optimizing patient enrollment and ensuring data quality in ongoing clinical trials.
- Neumora's net loss for 2025 was comparable to 2024, indicating ongoing financial challenges despite progress in clinical development.
Ladies and gentlemen, thank you for standing by. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to turn the call over to Helen Rubinstein, Vice President of Investor Relations and Corporate Strategy at Neumora. Please go ahead.
Good afternoon, and thank you for joining Neumora Therapeutics fourth-quarter and full year 2025 financial results conference call. Before we begin, I encourage everyone to visit the Investors and Media section of our website at neumoratx.com, where you can find the press release related to today's call. With me on the call today are Chief Executive Officer, Paul Berns; President, Josh Pinto; Chief Operating and Development Officer, Bill Aurora; Chief Scientific Officer, Nick Brandon; and Chief Financial Officer, Mike Milligan.
I'd like to point out that we will be making forward-looking statements during today's call, which are based on our current expectations
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
